Compare NRIX & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRIX | RUN |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2020 | 2015 |
| Metric | NRIX | RUN |
|---|---|---|
| Price | $25.65 | $8.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $30.50 | $18.80 |
| AVG Volume (30 Days) | 1.0M | ★ 6.2M |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 113.35 |
| EPS | N/A | ★ 1.04 |
| Revenue | $76,987,000.00 | ★ $858,578,000.00 |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | $48.05 | $4.54 |
| P/E Ratio | ★ N/A | $8.21 |
| Revenue Growth | ★ 99.31 | 12.97 |
| 52 Week Low | $8.20 | $8.19 |
| 52 Week High | $28.23 | $22.44 |
| Indicator | NRIX | RUN |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 43.27 |
| Support Level | $24.95 | $8.42 |
| Resistance Level | $28.23 | $9.40 |
| Average True Range (ATR) | 1.02 | 0.38 |
| MACD | -0.16 | 0.06 |
| Stochastic Oscillator | 40.83 | 36.78 |
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.